<code id='E117600D48'></code><style id='E117600D48'></style>
      • <acronym id='E117600D48'></acronym>
      <center id='E117600D48'><center id='E117600D48'><tfoot id='E117600D48'></tfoot></center><abbr id='E117600D48'><dir id='E117600D48'><tfoot id='E117600D48'></tfoot><noframes id='E117600D48'>
      • <optgroup id='E117600D48'><strike id='E117600D48'><sup id='E117600D48'></sup></strike><code id='E117600D48'></code></optgroup>
        5. <b id='E117600D48'><label id='E117600D48'><select id='E117600D48'><dt id='E117600D48'><span id='E117600D48'></span></dt></select></label></b><u id='E117600D48'></u>
          <i id='E117600D48'><strike id='E117600D48'><tt id='E117600D48'><pre id='E117600D48'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / Wikipedia / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-09-06 09:36:43 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：4
                                  
                                    
          
                                   
          Stock exchange
          Drew Angerer/Getty Images
          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 
          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.
          advertisement
          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Target recalls 2.2 million additional candles due to laceration, burn hazards
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles